PCN82 COST COMPARISON OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE VERSUS PEMETREXED AND CISPLATIN THERAPY IN PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL CANCER IN GERMANY – AN UPDATED ANALYSIS

Autor:	Bischoff, HG, Hermes, A, Heigener, DF, Cesaro-Tadic, S, Walzer, S, Nuijten, M
Zdroj:	In Value in Health 2010 13(3):A39-A39
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect Plný text